

Table S6. Sensitivity analysis results: HPV type distribution, incidence rates, and five-year risks using different eligibility criteria (Analysis 1) and different outcome assessment (Analysis 2)

HPV genotype	Sensitivity Analysis 1: LSIL or ASCUS enrollment cytology only (n=287) ^a				Sensitivity Analysis 2: Histologically confirmed CIN2+ cases only (n=340) ^b			
	N (%)	Incidence rate (95% CI) ^c	Hierarchical group-wise 5-year risks ^d	Log-rank p-value	N (%)	Incidence rate (95% CI) ^c	Hierarchical group-wise 5-year risks ^d	Log-rank p-value
Total HPV-positive	258 (89.9)	2.1 (1.3, 3.5)			298 (87.6)	2.4 (1.5, 3.7)		
High-risk HPV								
Any type	184 (64.1)	2.8 (1.6, 4.7)			215 (63.2)	3.1 (2.0, 4.9)		
16	28 (9.8) ^e	8.0 (3.6, 17.9) ^e	0.34	0.04	36 (10.6) ^e	8.3 (4.1, 16.6) ^e	0.34	0.02
18/45	29 (10.1)	1.2 (0.2, 8.3)	0.07		33 (9.7)	2.0 (0.5, 7.9)	0.12	
31/33/35/52/58	70 (24.4)	2.6 (1.1, 6.4)	0.11		84 (24.7)	2.7 (1.2, 6.1)	0.08	
39/51/56/59/68	96 (33.4)	2.3 (1.0, 5.0)	0.15		106 (31.1)	2.8 (1.4, 5.6)	0.16	
18	17 (5.9)	2.0 (0.3, 14.3)			20 (5.9)	3.2 (0.8, 12.9)		
31	17 (5.9)	2.6 (0.4, 18.2)			19 (5.6)	2.3 (0.3, 16.4)		
33	7 (2.4)	4.0 (0.6, 28.1) ^e			7 (2.1)	4.3 (0.6, 30.7) ^e		
35	12 (4.2)	0.0 (0.0, 13.9)			17 (5.0)	2.5 (0.4, 17.8)		
39	28 (9.8) ^e	3.1 (0.8, 12.4)			30 (8.8) ^e	4.3 (1.4, 13.3) ^e		
45	12 (4.2)	0.0 (0.0, 10.1)			13 (3.8)	0.0 (0.0, 9.5)		
51	30 (10.5) ^e	2.5 (0.6, 9.8)			33 (9.7) ^e	3.3 (1.1, 10.3)		
52	24 (8.4)	2.8 (0.7, 11.1)			28 (8.2)	2.4 (0.6, 9.8)		
56	16 (5.6)	1.9 (0.3, 13.8)			19 (5.6)	1.7 (0.2, 12.3)		
58	15 (5.2)	5.6 (1.4, 22.2) ^e			18 (5.3)	4.9 (1.2, 19.6) ^e		
59	24 (8.4)	1.4 (0.2, 9.9)			26 (7.6)	1.3 (0.2, 9.4)		
68	14 (4.9)	2.5 (0.4, 17.7)			16 (4.7)	2.2 (0.3, 15.3)		
Low-risk HPV only	73 (25.4)	0.5 (0.1, 3.7)			80 (23.5)	0.5 (0.1, 3.3)		
HPV-negative	29 (10.1)	2.7 (0.7, 10.9)			42 (12.4)	1.8 (0.5, 7.3)		

^a Sensitivity Analysis 1: LSIL n=195, ASCUS n=92; median follow-up time: 24.2 months; 17 progression events overall

^b Sensitivity Analysis 2: median follow-up time: 24.6 months; 17 progression events overall

^c Incidence rate per 1000 person-months; estimated with exponential accelerated failure time models for interval-censored data; for genotypes with zero events, estimated with Poisson exact method

^d Using hierarchical HPV risk groups from Demarco et al. (2020): HPV 16, else HPV 18/45, else HPV 31/33/35/52/58, and else HPV 39/51/56/59/68; risks estimated with Turnbull's nonparametric estimator for interval-censored data. For comparison, main analysis group-wise 5-year risks were 0.34, 0.12, 0.12, and 0.16, respectively (p=0.05)

^e Top 3 HPV types with highest frequency or incidence rate, as applicable (or more, in case of a tie)